BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer.
作者信息
Ottaiano Alessandro, Santorsola Mariachiara, Circelli Luisa, Ianniello Monica, Casillo Marika, Petrillo Nadia, Sabbatino Francesco, Cascella Marco, Perri Francesco, Capuozzo Maurizio, Albino Vittorio, Granata Vincenza, Izzo Francesco, Di Mauro Annabella, Berretta Massimiliano, Ruggiero Raffaella, Gualillo Oreste, Sirica Roberto, Nasti Guglielmo, Savarese Giovanni
机构信息
Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via Mariano Semmola, 80131 Napoli, Italy.
Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via Mariano Semmola, 80131 Napoli, Italy.
出版信息
Neoplasia. 2023 Oct;44:100930. doi: 10.1016/j.neo.2023.100930. Epub 2023 Aug 25.
Abstract
摘要
相似文献
1
BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer.BRAF p.V600E突变作为结直肠癌中真正寡转移和多转移疾病之间的分子界限。
Neoplasia. 2023 Oct;44:100930. doi: 10.1016/j.neo.2023.100930. Epub 2023 Aug 25.
2
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.免疫组织化学检测结直肠癌中的 BRAF V600E 突变。
Genes Chromosomes Cancer. 2013 Aug;52(8):748-52. doi: 10.1002/gcc.22070. Epub 2013 May 7.
3
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.BRAF 突变与手术治疗转移性结直肠癌肝转移患者生存和复发的关系。
JAMA Surg. 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996.
4
Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.Cdx2 在 BRAF 突变、高水平 CpG 岛甲基化表型和错配修复缺陷的结直肠癌锯齿状通路中的可能作用。
Int J Cancer. 2014 May 15;134(10):2342-51. doi: 10.1002/ijc.28564. Epub 2013 Nov 13.
5
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.BRAF 突变型转移性结直肠癌中国患者的临床病理特征及治疗疗效：一项回顾性观察研究
Chin J Cancer. 2017 Oct 16;36(1):81. doi: 10.1186/s40880-017-0247-y.
6
Metastatic pattern is a prognostic factor in BRAF mutant colorectal cancer.转移模式是 BRAF 突变型结直肠癌的预后因素。
Cancer Treat Res Commun. 2023;35:100714. doi: 10.1016/j.ctarc.2023.100714. Epub 2023 Apr 28.
7
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.新型RAF激酶和EGFR抑制剂BGB-283在BRAF突变型结直肠癌中显示出强大的抗肿瘤活性。
Mol Cancer Ther. 2015 Oct;14(10):2187-97. doi: 10.1158/1535-7163.MCT-15-0262. Epub 2015 Jul 24.
8
and Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.并发性结直肠癌标准化学疗法反应的预后和预测生物标志物：单机构研究。
Cells. 2020 Jan 15;9(1):219. doi: 10.3390/cells9010219.
9
Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.针对BRAF V600E突变型转移性结直肠癌对BRAF抑制的继发性和三发性耐药
JCO Precis Oncol. 2021 Nov;5:1082-1087. doi: 10.1200/PO.21.00107.
10
Improvements in Clinical Outcomes for -Mutant Metastatic Colorectal Cancer.KRAS 突变型转移性结直肠癌临床结局的改善
Clin Cancer Res. 2020 Sep 1;26(17):4435-4441. doi: 10.1158/1078-0432.CCR-19-3809. Epub 2020 Apr 6.
引用本文的文献
1
Clinical and genetic drivers of oligo-metastatic disease in colon cancer.结肠癌寡转移疾病的临床和遗传驱动因素
Neoplasia. 2025 Feb;60:101111. doi: 10.1016/j.neo.2024.101111. Epub 2024 Dec 21.
2
Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer.优化结直肠癌寡转移/寡复发的治疗策略
Cancers (Basel). 2023 Dec 27;16(1):142. doi: 10.3390/cancers16010142.
Zotero 插件